Pfizer's 6.7% Yield Looks Scary -- but the Dividend Story Is Stronger Than It Seems
Key Points Pfizer is a highly respected pharmaceutical company. The drug maker is dealing with a mismatch between its new drug development and patent expirations. Management is standing behind the dividend, and it has the room to keep paying it for now. 10 …